Subscribe To
SYRS / Syros Pharmaceuticals Is A Buy As New Trials Start
SYRS News
By Proactive Investors
October 2, 2023
Syros Pharmaceuticals undergoes leadership shakeup, workforce reduction
Syros Pharmaceuticals shares dropped on Monday after a series of shakeups at the biotech company. The firm is saying goodbye to its CEO, Nancy Simonia more_horizontal
By Zacks Investment Research
August 8, 2023
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of $1.11. This comp more_horizontal
By Zacks Investment Research
March 2, 2023
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. more_horizontal
By Seeking Alpha
February 8, 2023
Syros: Multiple Shots On Goal In Blood Cancer Space
Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene more_horizontal
By Seeking Alpha
January 15, 2023
Syros Pharmaceuticals A Buy Given Stock Price And Pipeline Potential (Rating Upgrade)
Syros Pharmaceuticals is developing cancer therapies. Its most advanced potential therapy is tamibarotene for MDS. more_horizontal
By Benzinga
April 11, 2022
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity more_horizontal
By Seeking Alpha
March 15, 2022
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Zacks Investment Research
March 15, 2022
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Tops Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.55% and 38.09%, respectively, for the quarter ended December 2021. Do more_horizontal